Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG) - PubMed (original) (raw)

. 2013 Jun 6;121(23):4769-77.

doi: 10.1182/blood-2012-10-461624. Epub 2013 Apr 30.

Richard F Schlenk, Peter Paschka, Anja Stölzle, Daniela Späth, Andrea Kuendgen, Marie von Lilienfeld-Toal, Wolfram Brugger, Hans Günter Derigs, Stephan Kremers, Richard Greil, Aruna Raghavachar, Mark Ringhoffer, Helmut R Salih, Mohammed Wattad, Heinz G Kirchen, Volker Runde, Gerhard Heil, Andreas L Petzer, Michael Girschikofsky, Michael Heuser, Sabine Kayser, Gudrun Goehring, Maria-Veronica Teleanu, Brigitte Schlegelberger, Arnold Ganser, Jürgen Krauter, Lars Bullinger, Hartmut Döhner, Konstanze Döhner

Affiliations

Free article

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

Verena I Gaidzik et al. Blood. 2013.

Free article

Abstract

In this study, we evaluated the frequency and prognostic impact of DNMT3A mutations (DNMT3A(mut)) in 1770 younger adult patients with acute myeloid leukemia (AML) in the context of other genetic alterations and the European LeukemiaNet (ELN) classification. DNMT3A(mut) were found in 20.9% of AMLs and were associated with older age (P < .0001), higher white blood cell counts (P < .0001), cytogenetically normal AML (CN-AML; P < .0001), NPM1 mutations (P < .0001), FLT3 internal tandem duplications (P < .0001), and IDH1/2 mutations (P < .0001). In univariable and multivariable analyses, DNMT3A(mut) did not impact event-free, relapse-free (RFS), or overall survival (OS) in either the entire cohort or in CN-AML; a negative prognostic effect was found only in the ELN unfavorable CN-AML subset (OS, P = .011). In addition, R882 mutations vs non-R882 mutations showed opposite clinical effects-unfavorable for R882 on RFS (all: hazard ratio [HR], 1.29 [P = .026]; CN-AML: HR, 1.38 [P = .018]) and favorable for non-R882 on OS (all: HR, 0.77 [P = .057]; CN-AML: HR, 0.73 [P = .083]). In our statistically high-powered study with minimized selection bias, DNMT3A(mut) represent a frequent genetic lesion in younger adults with AML but have no significant impact on survival end points; only moderate effects on outcome were found, depending on molecular subgroup and DNMT3A(mut) type.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources